Search PubMed⌕ Search

PubMed · 10472621

[Chromium carcinogenicity].

Abstract

Chromium belongs to the group of trace elements hich are essential in numerous functions of the human body. Chromium deficiency may be responsible for various dysfunctions, whereas exposure to chromium at higher concentrations is toxic and may lead to the occurrence of neoplastic diseases. Epidemiological studies of chromium exposure proved its carcinogenity, and thus the IARC recognised Cr(VI) and its compounds as one of ascertained carcinogens. Some findings of these studies were reviewed in the first part of this work. The second part presents some molecular aspects of chromium carcinogenity which are still the subject of medical research. The direct and indirect effects of chromium and its compounds on DNA are analysed as are the relationships between the level of chromium oxidation and carcinogenity, and between the presence of reductants and the kind of DNA damage. Methods for the assessment of chromium mutagenity and genotoxicity are also discussed, and special attention is paid to tests of mutation in bacteria and yeast as well as to sister chromatid exchange (SCE) test.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Trocha, J Antonowicz, R Andrzejak. 1999. [Chromium carcinogenicity].. https://searchpubmed.org/record/pubmed%3A10472621/chromium-carcinogenicity

Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite Search PubMed by Indiciae: BibTeX · RIS.

KEEP EXPLORING

Related citations

Synthesis, structural revision, and antioxidant activities of antimutagenic homoisoflavonoids from Hoffmanosseggia intricata.

Intricatinol and intricatin, the two homoisoflavonoids isolated from Hoffmanosseggia intricata, and two analogs have been synthesized from pyrogallol in three steps. The spectral data of synthetic intricatinol are in good agreement with those of natural metabolite, but the spectral data of intricatin are not corroborative with those of the natural product. The structure of intricatin has been thus revised to 8-methoxybonducellin, a compound isolated from Caesalpinia pulcherrima. The antioxidant activity of all the four homoisoflavonoids was determined by superoxide (NBT) and DPPH free radical scavenging methods. The synthetic analog 7,8-dihydroxy-3-[(3,4-dihydroxyphenyl)methylene]chroman-4-one displayed excellent activity in both methods.

Antimutagenic Agents↗

Synthesis and antigenotoxic activity of some naphtho[2,1-b]pyrano[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives.

In this study, some pyranotriazolopyrimidine derivatives were synthesised by reacting ethoxymethyleneamino derivatives with hydrazides. Their structures were elucidated by IR, (1)H NMR, and (13)C NMR spectroscopic data and elemental analyses. Antigenotoxic activity of the obtained compounds was tested in Escherichia coli PQ37 by using the SOS chromotest.

Antimutagenic Agents↗

The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids.

Selenium can have cancer chemopreventive activity, although the mechanism of action has not been well defined. Selenazolidine-4-(R)-carboxylic acids (SCAs) were devised as prodrugs of L-selenocysteine, to provide selenium in a form and at a concentration commensurate with cancer chemopreventive activity. In the present study, a series of selenazolidines has been evaluated in the Salmonella typhimurium TA98 tester strain and all were found to possess antimutagenic activity. There was little difference between the seven selenazolidines in their effectiveness against either benzo[a]pyrene (B[a]P) or 3,6-bis(dimethylamino)acridine (acridine orange), agents which differ in their requirement for mammalian enzyme bioactivation for mutagenicity. Antimutagenic activity against acridine orange was dependent on selenazolidine concentration, and EC50 values were in the 5-10 microM range. At 25 microM, the concentration tested in common for the two mutagens, the selenazolidines were more effective antimutagens against acridine orange than against B[a]P, with reductions in mutant frequency ranging from 54 to 71% for B[a]P and 79 to 93% for acridine orange. Efficacy against B[a]P was not enhanced when the concentration was increased to 50 microM. The similarity in efficacy among the selenazolidines against B[a]P mutagenicity, contrasted with inter-compound differences in their ability to inhibit S9 CYP1A activity. The CYP1A Ki values ranged from a low of 63 microM (2-[2'-hydroxyphenyl]SCA) to a high of 1.1mM (2-cyclohexylSCA), but all were above the concentration required to inhibit mutagenicity by 50%. Thus, all the SCAs possess antimutagenic activity against both B[a]P and acridine orange, the efficacy varies little between the individual selenazolidines, and for B[a]P, the efficacy is not proportional to the inhibitory effect on the mutagen bioactivating enzyme.

Antimutagenic Agents↗